The unpredictability of idiopathic sudden sensorineural hearing loss (ISSNHL) presents a challenge to preventive care. Our study confirms the potentially important role of the 3-T magnetic resonance imaging (MRI), and in particular of the 3-dimensional fluid-attenuated inversion-recovery (3D-FLAIR) sequence, in the diagnosis and prognosis of ISSNHL to guide medical treatment.
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UDDEN SENSORINEURAL HEARing loss (SSNHL) is an indirect sign of cochlear injury resulting from idiopathic causes (idiopathic SSNHL [ISSNHL])
It is defined as a sensorineural hearing loss of 30 dB or more over at least 3 contiguous audiometric frequencies that develops over a period of a few hours to 3 days. 1 Despite efforts to clarify its pathophysiologic characteristics, the cause of ISSNHL remains unclear. The hypothesized causes include viral infection, 2 vascular compromise, 3 disruption of cochlear membranes, 4 and the autoimmunity. 5 However, detailed investigation based on medical and physical examination, audiovestibular tests, blood examinations, and brain magnetic resonance imaging (MRI) studies with and without gadolinium administration shows a specific cause only in about 10% of patients. 6 The fluid-attenuated inversion-recovery (FLAIR) sequence is part of the routine protocol for MRI of the brain. There are emerging data in the scientific literature 7, 8 that the 3D-FLAIR sequence may provide diagnostic information in patients with ISSNHL, thus improving our possibility of detecting inner ear fluid anomalies by demonstrating alterations of the inner ear's fluid protein composition, conditions that are difficult to identify on T1-and T2-weighted MRIs. 9 However, the exact relationship between 3D-FLAIR findings and clinical signs is still unknown, and the role of 3D-FLAIR as an evaluative tool to discover prognostic indicators is only recently emerging. We therefore used the 3D-FLAIR MRI to investigate its diagnostic, clinical, and prognostic role in a selected population of patients affected by ISSNHL, and we compared our results with those of other centers.
METHODS
STUDY DESIGN AND PATIENTS
This retrospective clinical study involved 23 patients with unilateral ISSNHL (11 men and 12 women; mean [SD] age, 49.3 [18.5] years; age range, 20-78 years) who visited the Otolaryngology, Audiology, and Phoniatrics Unit of the University of Pisa between January 2010 and March 2011. The study was approved by the local ethics committee. Informed consent for the participation to the study was received from all patients.
The criteria used to define ISSNHL were the presence of a sensorineural hearing loss of 30 dB or more over at least 3 contiguous audiometric frequencies developed over a period of a few hours up to 3 days without obvious causes. 1 We excluded patients with progressive or fluctuating hearing loss. All patients underwent a unified diagnostic protocol to exclude known causes of sudden sensorineural hearing loss ( Table 1) .
Medical history was recorded for all patients, and all underwent physical and neurologic examinations and complete audiologic evaluations including otomicroscopy, impedance audiometry, speech audiometry, otoemissions, and auditory brainstem responses. Hearing levels were evaluated with pure-tone audiometry (Interacoustics; Amplifon) in a sound-isolated chamber. Hearing loss was defined by pure-tone average (PTA), calculated using thresholds at 0.5, 1.0, 2.0, and 4.0 KHz, following the standards of the National Institute on Deafness and Other Communication Disorders. 10 Audiometric assessment was made at the time of diagnosis, every 2 days during treatment, and after 3 months; the 3-month findings were considered the definitive posttreatment result. Furthermore, the degree of recovery was evaluated according to the Siegel criteria.
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Presence of vertigo, tinnitus, and time delay between ISSNHL onset and MRI were recorded. In cases of vertigo, patients underwent vestibular function evaluation with caloric test and videonystagmography (VNG).
As far as therapy is concerned, all patients were treated with intravenous (IV) 6-methylprednisolone, 1 bolus/d for 3 days, followed by a 30-day course at 1 mg/kg/d, tapered every 2 days.
MAGNETIC RESONANCE IMAGING
Magnetic resonance scans were performed using a 3-T system (Excite HD; General Electric Medical) with an 8-element phasedarray sensitivity-encoding head coil. All patients underwent MRI of the temporal bones using the following protocol:
1. Fast-inflow steady-state acquisition in 3 dimensions (3D FIESTA); repetition time (TR), 6.1 milliseconds; echo time (TE), 2.4 milliseconds; flip angle, 60Њ; isotropic voxel, 0.4 mm; slice thickness, 0.4 mm; acquisition time (TA) 10 minutes, 28 seconds; number of excitations (NEX), 2; bandwidth, 62.50 kHz; field of view (FOV), 14 cm, acquired in the axial plane to obtain high anatomic detail.
2. 3D-FLAIR; TR, 11.000 milliseconds; TE, 134 milliseconds; inversion time, 2581 milliseconds; bandwidth, 41.7 kHz; FOV, 25.6 cm; TA, 10 minutes 53 seconds; isotropic voxel, 1 mm using a 256 ϫ 256 matrix (512 ϫ 512 zip); echo train, 180; parallel imaging; sagittal acquisition; fat-suppression pulse acquired in the sagittal plane covering the entire brain volume.
3. Both sequences (1) and (2) may be reformatted in all planes maintaining the same signal to noise ratio. Postcontrast images were obtained shortly after IV administration of gadolinium (Gadovist; Bayer Schering Pharma) at a dose adapted to weight (0.2 mL/kg; flux, 1 mL/second) using both 3D-FLAIR and T1 FSE with fat-suppression sequences for comparison.
The imaging data regarding the 3D-FLAIR sequences were compared with 20 age-matched patients scanned using the same sequence for abnormalities other than with the inner ear. We also compared the data with the unaffected ear in unilateral involvement. All patients with other brain lesions, regardless of the presence of high-intensity signal in the inner ear, were excluded from the study. The Pearson correlation coefficient was used for quantifying the relationship between Gaussian distributed variables; for skewed variables, the Spearman correlation index was used. PϽ.05 was considered statistically significant.
STATISTICAL ANALYSIS
Data are presented as mean (SD) and as proportions with percentages, as indicated. Statistical analyses were performed using Matlab (MathWorks).
RESULTS
The characteristics of the 23 patients are summarized in Table 2 . Thirteen of the 23 patients with ISSNHL showed high-intensity signals in the affected inner ear on precontrast 3D-FLAIR (57%), so we considered them 3D-FLAIR positive. In contrast, the group of 10 patients with no high-intensity signal in the affected ear was considered 3D-FLAIR negative. The 3D-FLAIR-negative group did not show any other signal alteration and/or postcontrast enhancement in any sequence. The side of the abnormal findings on 3D-FLAIR MRI correlated with the side of the affected ear in all patients. No significant differences were observed between the 2 groups in age (P = .31), sex (P = .13), affected side (P = .16), and presence of tinnitus (P = .10). In contrast, at the onset of ISSNHL, the incidence of vertigo in the 3D-FLAIR-positive and 3D-FLAIR-negative groups differed significantly (8 of 13 [62%] and 2 of 10 [20%], respectively) (P = .04).
The period between the MRI study and the onset of ISSNHL was a mean (SD) of 17 (12) days, with no significant differences in the 3D-FLAIR-positive and 3D-FLAIR-negative groups (P = .06).
Regarding audiologic findings, mean (SD) pretreatment PTA for the whole group was 77.4 (21.2) dB, with a significantly worse value in the 3D-FLAIR-positive group (85.7 [23.1] dB) compared with the 3D-FLAIRnegative group (66.6 [12.5] dB) (P = .04). In contrast, no relevant differences between the 2 groups were observed in the posttreatment PTA values (P = .41) and the posttreatment gain (⌬PTA), calculated as the difference between pretreatment and posttreatment PTA values (P = .34). In the group of 23 patients, the 3-month outcome was not influenced by the presence of vertigo (P = .35) or tinnitus (P = .26).
For the 3D-FLAIR-positive group, the distribution of the MRI signal is summarized in Table 3 . Of the 13 3D-FLAIR-positive patients, 7 (54%) showed multiple subsites of high-intensity signal, while 6 patients (46%) had only 1 subsite of hypersignal (5 cases in the cochlea only, and 1 case in the cochlear nerve) (Figure 1) . In 3 patients (23%), there was high-intensity signal in T1-weighted MRI images; in 3 patients (23%), a highintensity signal only in the 3D-FLAIR sequence; and in 7 From the combined analyses of T1 and FLAIR sequences, and from the findings of other researchers, 7, 9, 12 we identified 3 possible radiologic patterns:
Pattern 1: presence of high-intensity signal in the T1-weighted sequence, owing to the presence of intracellular and extracellular methemoglobin, and in 3D-FLAIR images, owing to the increased protein content in the membranous fluid secondary to the presence of methemoglobin (Figure 2 ), potentially consistent with intracochlear hemorrhage.
Pattern 2: presence of high-intensity signal in 3D-FLAIR images, owing to the increased protein content in the membranous fluid secondary to the presence of a protein exudate, while FIESTA and T1 sequences did not show any signal alteration (Figure 3) , potentially consistent with acute inflammatory process.
Pattern 3: contrast enhancement after gadolinium injection is currently considered a result of a breakdown of the blood labyrinth barrier (BLB) 7 ; it can be associated with either of the diagnoses from pattern 1 and pattern 2, and it is expressed by high-intensity signal on T1 images and enhancement of the high-intensity signal on the 3D-FLAIR images (Figure 4) . This pattern may be consistent with breakdown of the BLB.
We therefore studied, by means of the independent samples t test, whether some of the 3D-FLAIR-related factors could influence the outcome and if they could be considered prognostic. From our statistical analysis, we concluded that the 3D-FLAIR diagnosis of a possible acute inflammatory process or intracochlear hemorrhage does not influence patient outcome, measured as ⌬PTA, in a statistically significant way (P = .26), nor does the diagnosis of BLB breakdown (P = .47). The correlations among some clinical features, such as vertigo and tinnitus, and the site of the hypersignal at 3D-FLAIR MRI were evaluated in all 3D-FLAIRpositive subjects, and we found that a 3D-FLAIR hypersignal in the vestibule or in the semicircular canals was related to vertigo in a statistically significant way (P = .04 or P = .01, respectively) ( Table 4) . Such correlations could not be done for tinnitus, as all 3D-FLAIRpositive patients had it.
The intensity range of the hypersignal, expressed as the number of subsites with 3D-FLAIR hyperintensity, was not related to the initial hearing level (P = .16) nor to the final outcome indicated as ⌬PTA (P = .95).
DISCUSSION
The most controversial aspect of ISSNHL is the complete lack of unequivocal diagnostic and pathogenetic elements in the patients' history. An improvement of our knowledge is urgently needed, especially when considering that there is an ongoing discussion about better treat- ment of ISSNHL (intratympanic vs systemic therapy) 13 that still necessitates more information to be guided. The 3D-FLAIR 3-T MRI sequence may potentially be a tool for improving diagnostic accuracy, for guiding therapeutic decisions, and for serving as a prognostic factor in ISSNHL. Being insensitive to flux artifacts, it causes signal nulling of the cerebrospinal fluid and normal endoperilymphatic fluid, as we noticed in the control group, which has physicochemical composition similar to it. In our patients, it seems plausible to assume that the endoperilymphatic fluid creates a hyperintense signal when its composition changes due to pathologic conditions like hemorrhage (pattern 1) or inflammatory exudate (pattern 2). Thus, 3D-FLAIR hyperintensity indicates the modification of the inner ear protein composition that can be ascribed to a minor hemorrhage or to an acute inflammatory process. 9 Also, 3D-FLAIR imaging can detect the BLB breakdown as the enhancement of the endolabyrinthic fluid signal and/or nerve signal after gadolinium injection owing to its high sensitivity to magnetic susceptibility. 7 In our experience 3D-FLAIR imaging is more sensitive to hematolabyrinthic and hematonervous barrier breakdown than T1 imaging, with fat suppression increasing the diagnosis accuracy.
On the basis of our group data, we can state that 3D-FLAIR provides an approximately 50% increment in diagnostic sensitivity in patients with ISSNHL who are otherwise healthy. Our finding of 57% of 3D-FLAIRpositive patients is similar to the findings of other authors: Cadoni et al 9 14 (64.5%). In agreement with these authors, our group found no intrinsic differences in terms of patient age, sex, and laterality of the affected ear.
Furthermore, our 3D-FLAIR MRI protocol had no significant technical differences from those used in the studies of Cadoni et al, 9 Yoshida et al, 14 Sone et al, 15 Ishida et al, 16 Tanigawa et al, 17 and Lee et al. 7 Our mean (SD) delay between ISSNHL onset and 3D-FLAIR MRI (17 days [12] ; range, 1-60 days) was similar to that already reported in literature, and in particular similar to the findings of Sugiura et al 4, 12 (3-20 days) . However, this time interval was not consistently reported by all authors, and in particular, data are not available in the studies by Sone et al 15 and Lee et al. 7 The time factor may be an element that significantly affects 3D-FLAIR MRI findings, which may be negative within 90-150 days after the onset of ISSNHL.
14 Moreover, we have to consider that some minor findings, such as a slight 3D-FLAIR hyperintensity, may be masked by steroid therapy, which in our group, as in those of other researchers, is initiated at ISSNHL diagnosis and not after the execution of the MRI. In fact, as Ramos et al 18 suggest, a certain number of normal-appearing MRIs might provide better information if they were performed before the start of steroid therapy. If the diagnostic and prognostic value of 3D-FLAIR MRI in ISSNHL is to be further confirmed and validated, the interval between the onset of ISSNHL, the execution of the MRI, and the beginning of the therapy must be reduced to a minimum. This should happen very soon and at an organizational level.
Herein, we introduce what we believe are 3 new radiologic patterns to better delineate the significance of the generic term of hypersignal found in other authors' works. 7, 9 Our definitions are easily understandable, reproducible, and easily applicable to future studies. In our group, for the moment, those patterns have no prognostic value, but we think that larger samples may provide a more interesting interpretation. In particular, we will be able to confirm or disconfirm that BLB breakdown can be considered an unfavorable prognostic factor, as previously suggested. 12 For the moment, this is nothing more than an impression because it is drawn on the basis of the clinical course of 1 patient belonging to a small group sample (N = 8). 12 The aim of our study was to provide a correct interpretation of the 3D-FLAIR MRI findings, to correlate the findings with the patients' clinical features, and to find out if they have some prognostic value of clinical interest.
First, our experience confirms the high clinical value of the 3D-FLAIR findings 7 : there was a 100% correlation between the affected site and the hypersignal, and we never found a contralateral alteration and/or a hypersignal in the control group. This confirms the high reliability of the 3D-FLAIR pulse sequence. Furthermore the 3D-FLAIR sequence proved to be more sensitive than the T1-weighted sequence in pointing out BLB breakdown. Moreover, high diagnostic specificity was obtained in association with the T1 sequence, which reveals the presence of methemoglobin within the labyrinth due to hemorrhage.
In our group, the initial PTA had a good correlation with 3D-FLAIR MRI findings, with a statistically significant association in the 3D-FLAIR-positive group (P = .04). We observed that a worse initial PTA together with a hy- 
